Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. (Q54641353)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16181301%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

title

Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16181301%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference

1 reference

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16181301%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Tibor Hlavaty

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16181301%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

8

Rutgeerts P

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16181301%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

author name string

Pierik M

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16181301%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Henckaerts L

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16181301%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Ferrante M

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16181301%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Joossens S

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16181301%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

van Schuerbeek N

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16181301%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Noman M

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16181301%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

language of work or name

English

0 references

publication date

1 October 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16181301%20AND%20SRC:MED&resulttype=core&format=json

Alimentary Pharmacology & Therapeutics

7 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16181301%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16181301%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16181301%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

613-626

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16181301%20AND%20SRC:MED&resulttype=core&format=json

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

7 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02635.X

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02635.X

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02635.X

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02635.X

Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02635.X

Predictors of response to infliximab in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02635.X

Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02635.X

Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02635.X

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02635.X

Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02635.X

The biochemistry of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02635.X

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02635.X

Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02635.X

NOD2/CARD15 does not influence response to infliximab in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02635.X

Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02635.X

ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02635.X

A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02635.X

The CD95(APO-1/Fas) DISC and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02635.X

Cell-death signaling and human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02635.X

A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02635.X

A newly identified single nucleotide polymorphism in the promoter of the matrix metalloproteinase-1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02635.X

Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02635.X

Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02635.X

The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02635.X